drugset
drugset / Trial / NCT00241345

Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant

NCT00241345 ↗

Phase 3 Terminated 39 enrolled Washington University School of Medicine
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this trial is to determine if preemptive therapy with oral valganciclovir is as effective as intravenous ganciclovir in clearing cytomegalovirus (CMV) viremia as determined by quantitative CMV polymerase chain reaction (PCR) assay in patients who have undergone bone marrow or peripheral blood stem cell transplant.

Timeline

Start
2004-06
Primary completion
2007-11
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganciclovir Small molecule 5 mg/kg Intravenous
Subject Valganciclovir Small molecule 900 mg Oral

Indications

cytomegalovirus infection